N-(2-isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide: RN given refers to the (S-(R*,S*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128564 |
| CHEMBL ID | 45483 |
| SCHEMBL ID | 9284838 |
| MeSH ID | M0180237 |
| Synonym |
|---|
| n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide |
| HTA , |
| DB07926 |
| CHEMBL45483 , |
| sc-44463 |
| bdbm50104969 |
| n-[3-(n''-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide |
| (r)-n*4*-hydroxy-2-isobutyl-n*1*-[(s)-2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide |
| n*4*-hydroxy-2-isobutyl-n*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide |
| (2r)-n'-hydroxy-n-[(2s)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide |
| n-(2-isobutyl-3-(n'-hydroxycarbonylamido)propanoyl)-o-methyltyrosinemethylamide |
| 104408-38-0 |
| ihp-tyr-menh2 |
| butanediamide, n4-hydroxy-n1-(1-((4-methoxyphenyl)methyl)-2-(methylamino)2-oxoethyl)-2-(2-methylpropyl)-, (s-(r*,s*))- |
| SCHEMBL9284838 |
| sc44463 |
| (2r)-n~4~-hydroxy-n~1~-[(1s)-1-(4-methoxybenzyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)butanediamide |
| (r)-n4-hydroxy-2-isobutyl-n1-((s)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl)succinamide |
| Q27097160 |
| DTXSID10908962 |
| n~4~-hydroxy-n~1~-[1-hydroxy-3-(4-methoxyphenyl)-1-(methylimino)propan-2-yl]-2-(2-methylpropyl)butanediimidic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Further optimization resulted in compound 11, a potent, selective, and orally bioavailable inhibitor of aggrecanase." | ( Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. Arner, EC; Chao, M; Christ, D; Covington, MB; Decicco, CP; Liu, RQ; Magolda, RL; Newton, R; Pratta, MA; Qian, M; Reddy, G; Ribadeneira, MD; Shi, E; Tortorella, M; Wasserman, ZR; Wexler, RR; Yao, W, 2001) | 0.31 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Interstitial collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0115 | 0.0002 | 0.8502 | 10.0000 | AID108753; AID1340114 |
| Interstitial collagenase | Homo sapiens (human) | Ki | 0.0010 | 0.0003 | 0.4948 | 7.0000 | AID108923 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0060 | 0.0000 | 1.2848 | 10.0000 | AID107155 |
| 72 kDa type IV collagenase | Homo sapiens (human) | Ki | 0.0010 | 0.0000 | 0.3466 | 3.0000 | AID107318 |
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 0.0300 | 0.0000 | 1.1484 | 10.0000 | AID107498 |
| Matrilysin | Homo sapiens (human) | IC50 (µMol) | 0.0300 | 0.0014 | 2.0859 | 10.0000 | AID107816 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | Ki | 0.0010 | 0.0002 | 0.1281 | 0.8000 | AID108164 |
| Neutrophil collagenase | Homo sapiens (human) | Ki | 0.0007 | 0.0002 | 0.1797 | 2.1000 | AID107980 |
| Collagenase 3 | Homo sapiens (human) | IC50 (µMol) | 0.0010 | 0.0000 | 0.7675 | 10.0000 | AID1340115 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (80.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||